Explain this page
Arphra AIPlain-English read on Avis Budget Group, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for CAR.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.69% | +0.38% | +5.05% | +84.65% | +32.09% | +37.78% | +57.48% | +0.56% | +106.81% | +442.83% | +8696.02% |
Aftermarket
LiveLast trade
$176.80
1 sh
Bid
$175.30
100 sh
Ask
$178.00
154 sh
Spread
$2.700
Sector & industry today
LiveSectors
- Technology+2.80%
- Utilities+1.81%
- Industrials+1.63%
- Healthcare+1.00%
- Energy+0.92%
- Basic Materials+0.08%
- Real Estate-0.08%
- Communication Services-0.60%
- Consumer Cyclical-0.74%
- Financial Services-1.02%
- Consumer Defensive-1.60%
Top industries (issuer's industry highlighted)
- Rental & Leasing Services+2.34%
- Broadcasting+7.34%
- Computer Hardware+5.53%
- Software - Infrastructure+4.49%
- Engineering & Construction+4.25%
- Semiconductors+3.96%
- Financial - Capital Markets+3.56%
- Oil & Gas Drilling+3.49%
- Telecommunications Services-3.18%
- Beverages - Non-Alcoholic-3.14%
- Medical - Healthcare Information Services-2.98%
- Coal+2.93%
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $124.83 (-29.39%)
Total assets
$32.19B
Total debt
$31.17B
Cash & equiv
$519M
Operating CF
$3.3B
Free cash flow
-$11.98B
Buybacks
-$7M
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphomaaccessnewswire.com·Jun 04, 2026
- Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphomaaccessnewswire.com·Jun 04, 2026
- Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsglobenewswire.com·May 12, 2026
- Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsglobenewswire.com·May 12, 2026
- OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studiesglobenewswire.com·May 12, 2026
- OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studiesglobenewswire.com·May 12, 2026
- Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapyprnewswire.com·May 11, 2026
- Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseasesglobenewswire.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $2.53B | -$283M | $-8.02 |
| Q4 Dec 2025 | $2.66B | -$747M | $-21.22 |
| Q3 Sep 2025 | $3.52B | $359M | $10.11 |
| Q2 Jun 2025 | $3.04B | $4M | $0.11 |
| Q1 Mar 2025 | $2.43B | -$505M | $-14.35 |
| Q4 Dec 2024 | $2.71B | -$1.96B | $-55.66 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $11.65B | $1.28B | -$889M | $-25.26 | -7.63% |
| FY 2024 | $11.79B | $1.5B | -$1.82B | $-51.23 | -15.45% |
| FY 2023 | $12.01B | $2.35B | $1.63B | $42.06 | +13.59% |
| FY 2022 | $11.99B | $3.28B | $2.76B | $57.11 | +23.04% |
| FY 2021 | $9.31B | $2.09B | $1.29B | $19.44 | +13.80% |